A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

Blood Adv. 2018 Jul 24;2(14):1719-1737. doi: 10.1182/bloodadvances.2017011502.

Abstract

Despite considerable advances in our understanding of the pathophysiology of graft-versus-host disease (GVHD), its prediction remains unresolved and depends mainly on clinical data. The aim of this study is to build a predictive model based on clinical variables and cytokine gene polymorphism for predicting acute GVHD (aGVHD) and chronic GVHD (cGVHD) from the analysis of a large cohort of HLA-identical sibling donor allogeneic stem cell transplant (allo-SCT) patients. A total of 25 SNPs in 12 cytokine genes were evaluated in 509 patients. Data were analyzed using a linear regression model and the least absolute shrinkage and selection operator (LASSO). The statistical model was constructed by randomly selecting 85% of cases (training set), and the predictive ability was confirmed based on the remaining 15% of cases (test set). Models including clinical and genetic variables (CG-M) predicted severe aGVHD significantly better than models including only clinical variables (C-M) or only genetic variables (G-M). For grades 3-4 aGVHD, the correct classification rates (CCR1) were: 100% for CG-M, 88% for G-M, and 50% for C-M. On the other hand, CG-M and G-M predicted extensive cGVHD better than C-M (CCR1: 80% vs. 66.7%, respectively). A risk score was calculated based on LASSO multivariate analyses. It was able to correctly stratify patients who developed grades 3-4 aGVHD (P < .001) and extensive cGVHD (P < .001). The novel predictive models proposed here improve the prediction of severe GVHD after allo-SCT. This approach could facilitate personalized risk-adapted clinical management of patients undergoing allo-SCT.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Allografts
  • Child
  • Child, Preschool
  • Cytokines / genetics*
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease / genetics*
  • Hematologic Neoplasms / genetics*
  • Hematologic Neoplasms / therapy
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Models, Genetic*
  • Polymorphism, Genetic*
  • Retrospective Studies
  • Stem Cell Transplantation*

Substances

  • Cytokines